Financial Review: Prelude Therapeutics (NASDAQ:PRLD) vs. Nutriband (NASDAQ:NTRB)

Prelude Therapeutics (NASDAQ:PRLD) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Prelude Therapeutics and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$7.00 million	19.85	-$127.17 million	($1.47)	-1.50
Nutriband	$2.14 million	25.73	-$10.48 million	($3.07)	-1.47

Nutriband has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Prelude Therapeutics and Nutriband, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1	0	2	0	2.33
Nutriband	1	1	0	0	1.50

Prelude Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 81.00%. Given Prelude Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Prelude Therapeutics is more favorable than Nutriband.

Volatility & Risk

Prelude Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Profitability

This table compares Prelude Therapeutics and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-121.16%	-84.93%
Nutriband	-560.89%	-133.22%	-114.00%

Summary

Prelude Therapeutics beats Nutriband on 10 of the 14 factors compared between the two stocks.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.